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The last four dialogues of “Romeo and Juliet” 
William Shakespeare 
1595 
“Capulet head 
    O brother Montague, give me thy hand. 
    This is my daughter's jointure, for no more 
    Can I demand. 
Montague head  
    But I can give thee more; 
    For I will raise her Statue in pure gold, 
    That whiles Verona by that name is known, 
    There shall no figure at such rate be set 
    As that of true and faithful Juliet. 
Capulet head 
    As rich shall Romeo's by his lady's lie- 
    Poor sacrifices of our enmity! 
Prince Escalus of Verona 
    A glooming peace this morning with it brings. 
    The sun for sorrow will not show his head. 
    Go hence, to have more talk of these sad things; 
    Some shall be pardon'd, and some punished; 
    For never was a story of more woe 
    Than this of Juliet and her Romeo.” 
 
 
 
  
   
  
ABSTRACT 
Background 
Although there has been a large number of improvements in prevention and care, coronary 
heart disease (CHD) was one of the main causes of death in 2010 around the world. The 
majority of CHD deaths are due to myocardial infarction (MI) and occur out-of-hospital. The 
research regarding determinants of MI fatality including out-of-hospital deaths is scant. 
Aims 
The overall aim of this project was to increase knowledge about the determinants of MI 
fatality in men and women from the Stockholm general population who suffer a first MI. 
Specific aims were to: 1) validate questionnaire data collected from close relatives of MI 
patients, 2) assess how known cardiometabolic risk factors are associated with MI fatality, 3) 
describe which comorbidities are the most common among fatal MI cases and to assess if 
they are associated to MI fatality, and 4) assess whether low-grade inflammation is associated 
to fatality of future coronary events. 
Methods 
Using material from the Stockholm Heart Epidemiology Program (SHEEP), a case-control 
study, the validity of questionnaire data provided by spouses/common-law spouses (proxy 
respondents) of non-fatal MI cases regarding 82 exposures was valuated. Using conditional 
logistic regression we calculated for each of the exposures, a “proxy bias”, based on 
information collected from 1) MI cases and controls [odds ratio A] and 2) proxies and the 
same set of controls [odds ratio B]. Disagreement was measured by calculating the ratio 
between odds ratio B and odds ratio A; 95% confidence intervals (CI) were calculated using 
resampling bootstrap with replacement.  
From the SHEEP, an inception cohort of first time MI cases was formed. Data were retrieved 
from questionnaires (filled in by a close relative if the case was fatal), physical examinations 
(for non-fatal cases), national registers and autopsy reports. Associations between selected 
cardiometabolic risk factors and MI fatality were assessed through calculations of risk ratios 
(RR) with 95% confidence intervals (CI) using binomial regression with log link. Presence of 
comorbidities among the fatal MI cases was mapped out and the number of previous 
hospitalizations was assessed. Associations between specific comorbidities, as well as 
number of previous hospitalizations, and MI fatality were assessed using the same modelling 
as for the cardiometabolic risk factors. A structured review of autopsy data was performed to 
identify additional indicators of comorbidities in fatal MI cases.  
Using material from the AMORIS cohort, sex specific associations between low-grade 
inflammation (using a score of five biomarkers: C-reactive protein, haptoglobin, white blood 
cell count, uric acid and albumin) and a fatal outcome in subjects who subsequently 
experienced a first coronary event were assessed. Odds ratios were calculated with 95% CI 
using logistic regression.  
  
Results 
For the vast majority of the exposures considered in the validation study, there was no 
significant disagreement between reports from MI patients and proxies. However, leisure 
time physical inactivity was overestimated by proxies compared to MI patients. 
Diabetes, but not hypertension and hyperlipidemia, was associated with MI fatality. 
Overweight, as compared to normal BMI, was inversely associated with MI fatality; the 
results for obesity went in the same direction. The results were adjusted for age, current 
smoking, parental history of premature cardiac death, number of previous hospitalizations, 
educational level, disposable income, and other cardiometabolic risk factors. 
An increased number of previous hospitalizations was associated with MI fatality after 
adjustments for sex, age and disposable income. Among comorbidities identified as prevalent 
in fatal cases, the following were, after adjustments (where possible), associated with 7-day 
fatality: heart failure, stroke, diabetes, alcoholism, psychiatric diseases, cancer, kidney 
diseases, epilepsy, rheumatoid arthritis and asthma. Indicators of comorbidities identified 
from autopsy data included silent MI, severe abdominal aortic atherosclerosis, liver steatosis, 
and underweight.  
An elevated inflammation score was after adjustments by age at the time of the coronary 
event, calendar year of the coronary event, diabetes, level of education, serum total 
cholesterol, serum triglycerides, and angina associated with increased fatality of future 
coronary events, both in men and in women.  
Conclusions  
MI patients and their spouses similarly reported data on a wide range of exposures including 
traditional cardiovascular risk factors, leisure time physical inactivity being an exception.  
Among the cardiometabolic factors under study, diabetes and presence of a low-grade 
inflammation, but not hypertension and hyperlipidemia was associated with an increased MI 
fatality. Overweight was associated to a decreased MI fatality. Repeated prior hospitalizations 
and/or heart failure, diabetes, stroke, psychiatric disease, alcoholism, cancer, renal diseases, 
epilepsy, rheumatoid arthritis and asthma were associated with increased MI fatality. 
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1 BACKGROUND 
1.1 GLOBAL PERSPECTIVE OF CORONARY HEART DISEASE 
Cardiovascular disease (CVD) includes diseases of the heart, blood vessels in the brain and 
blood vessels of the heart, such as coronary heart disease (CHD), stroke and heart failure. 
CVD killed about 17 million persons in 2010 and it is estimated that 23 million persons will 
die in 2030 due to CVD (1).  Cardiovascular disease (CVD) is a serious global health 
problem. Among CVD, CHD was responsible for about 7 million deaths worldwide during 
2010 (2). The highest rates of CHD mortality occur in Surinam, Russia, Central Asia, the 
Middle East, North Africa, India and Eastern Europe, while the lowest occur in the high 
income regions of Asia Pacific and sub-Saharan Africa (2). The world distribution of CHD 
mortality is shown in Figure 1. 
 
 
 
Figure 1. Map of age-standardized CHD mortality rate per 100 000 persons in 21 world 
regions. Source: Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Murray CJ, 
et al. Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to 2010: 
the Global Burden of Disease 2010 study (2). Published with permission of the journal. 
Survival of the acute phase after a myocardial infarction (MI) or a CHD event varies over 
countries (3-7) although for many countries such statistics are not available. Papers 
describing the survival after a MI/CHD in United States, Australia, Sweden, the Netherlands 
and some European cities show that between 15% and 43% of individuals who suffer a fatal 
MI/CHD event die shortly after the event (3-8). The majority of these fatal events occur in 
individuals that were not admitted to hospital (3, 6-8). A recent publication from the National 
Board of Health and Welfare in Sweden shows a decrease in the fatality of the first MI from 
1987 to 2015 in Sweden (4). The publication also shows that about half of deaths during the 
first year after coronary event symptoms occurs within 24 hours regardless in which year the 
event happened, as shown in Figure 2 (4).  
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Figure 2. Proportion of deaths occurring within 0, 28 and 365 days among Swedish men and 
women older than 20 years old who suffered a first MI. Source: Socialstyrelsen, Statistik om 
hjärtinfarkter 2016 (Statistics on Myocardial Infarction 2016 In Swedish language) (4).   
1.2  POSSIBLE DETERMINANTS OF MI FATALITY 
The natural history of disease is defined as the course of a disease from pathological onset to 
resolution (9). The natural histories of several diseases are rather well known and often taught 
as part of basic medical training. The knowledge of the natural history of a given disease is 
important in order to better understand the mechanisms behind the disease. Such knowledge 
may enhance prevention of undesirable outcomes, for example death. Risk factors may 
increase the risk of developing a disease, but these risk factors may also act at different stages 
of a disease, determining its progress and prognosis. In MI, for example, the risk factors 
contributing to its onset may not necessarily be the same as those acting in the acute phase 
affecting the short-term outcome. In animal models, biomarkers with potential influence on 
survival in the acute phase of an MI have been identified (10-12) but research is scant. 
Epidemiological studies aiming at increasing knowledge about determinants of MI fatality 
are rather limited, in particular studies that consider out-of-hospital deaths (13-15). The 
presence of low-grade inflammation is one of the specific factors hypothesized to have a role 
(16, 17).    
1.3 CHD, MI AND SUDDEN DEATH  
CHD is an unbalanced supply/demand of oxygen to the heart muscle. CHD is mainly related 
to insufficiency of the function of coronary arteries that leads to localized myocyte ischemia 
(18) which leads to several symptoms, most commonly chest pain. If the clinician finds 
evidence that the ischemia leads to death of myocytes it is referred to as an MI, otherwise it is 
called angina (18). Angina is classified as stable when symptoms (usually chest pain) do not 
appear at rest, otherwise it is unstable.  
In MI, there is a leakage of intracellular contents that leads to detection of cardiac enzymes in 
blood and a local release of several damage associated molecular patterns (DAMP) leading to 
a severe sterile inflammation (19). In addition, there is also lateralization of gap junctions that 
  3 
might lead to electrocardiographic changes and arrhythmias (20). There have been changes 
over time in the MI diagnostic criteria. These changes reflect improvements in the technology 
to better detect small amounts of leakage of intracellular matter (21).  
The dysfunction of the coronary vessels leading to MI is often related to a sudden change in 
atherosclerosis plaques (18). But there are other rare causes: the spasm of large coronary 
artery (22) and “bridging” of cardiac tissue over the large coronary arteries (23). An acute MI 
can be associated with acute heart failure, arrhythmias, or mechanical complications (24).   
MI can be ascertained as a cause of death using the same criteria as for diagnosing it in a 
living person, if these criteria are applied when the case is alive. However, due to the 
suddenness of the event, the lack of time to take samples and to assess the anamnesis of the 
patient, MI as a cause of death can be asserted observing autopsy findings as those described 
in detail by Kumar et al. (25), as well as by Knight et al. (26). These autopsy changes reflect 
how long the person suffered MI symptoms before death. According to Kumar et al., findings 
of an MI can be detected using electron microscopy if the onset of symptoms started at least 
half an hour before the death (25). If light microscopy is used, pathological findings can be 
detected if death takes place after at least 4 hours of the onset of symptoms (25, 26). An MI 
can also be detected if there are signs of coronary occlusion regardless the myocardial 
findings (25, 26). When the clinician in charge of the death investigation suspects an MI as a 
cause of death but the autopsy is lacking or it is not clear for ascertaining it as cause of death, 
then the case will usually be considered a “fatal CHD”. 
Sudden death is defined by a sudden loss of pulse in a person who was apparently healthy 24 
hours before death (23, 27), although some authors use a shorter period of time in their 
definition (26). Sudden death is commonly caused by heart diseases, which include CHD 
(27). However, there are several non-cardiac diseases that might cause this syndrome and 
each forensic pathology book dedicates a whole chapter to describe all its possible causes (23, 
26, 28).  
1.4 POSSIBLE DETERMINANTS OF MI FATALITY 
1.4.1 Main exposures assessed in this thesis 
1.4.1.1 Cardiometabolic risk factors 
1.4.1.1.1 Diabetes 
Diabetes has consistently been identified as a relevant risk factor of in-hospital MI fatality 
(15, 29-33). However; studies that also consider out-of-hospital MI/CHD do not show so 
clear picture;  some of these studies agree with studies based solely on hospitalized MI 
patients (15, 32) and others show no association (13, 14).  
1.4.1.1.2 Hypertension 
Whether hypertension associates with MI/CHD fatality is not clear from the literature. 
Among studies where out-of-hospital CHD cases are included, some studies show no 
association (13, 15), whereas other ones show an increased MI/CHD fatality (14, 34). 
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Studies including hospitalized MI cases also show mixed results, some of them show no 
association (30, 35-38) but other studies show decreased MI/CHD fatality (29, 39). 
1.4.1.1.3 Overweight, obesity and BMI 
Overweight and obesity have been studied in relation to fatality of first time MI in hospital 
settings and in meta-analysis, showing an inverse association (40).  
Overweight and obesity have not been thoroughly assessed in studies that include out-of-
hospital CHD deaths. However, a previous paper shows similar body mass index (BMI) 
measurements for fatal CHD and non-fatal MI (14). 
1.4.1.1.4 Hyperlipidemia 
Serum cholesterol levels were not found associated with fatality of future CHD events in 
previous literature (13, 14).  
1.4.1.2 Comorbidities 
Comorbidity may be defined as a medical condition or a set of them existing simultaneously 
with, and independent of, another medical condition (41). Comorbidity has been associated to 
increased 30-day fatality of events in a coronary ward in Spain using the Charlson scale (42).  
Dudas et al. have shown a list of selected comorbidities with different associations to 28-day 
MI fatality according to data from Swedish national registers;  the results show that most of 
those comorbidities increase MI fatality (5). 
Most of the previous studies assessing the role of selected comorbidities in relation to MI 
fatality were performed using an in-hospital setting. Elixhauser et al. state that 12 
comorbidity groups, out of 30 they defined, increase the risk of dying in-hospital after having 
been admitted with an MI diagnosis, while seven of these groups decrease the risk of dying; 
the study was performed  in California, USA (43).   
1.4.1.3 Inflammation 
Inflammation represents a set of events that happens when the immune system is triggered 
due to tissue damage. Inflammation assessed using a set of acute phase proteins has been 
associated with increased fatality of future coronary events in a population-based cohort from 
Malmö, Sweden (17). 
Other literature on this topic involves the assessment of individual biomarkers of 
inflammation, with diverse results regarding associations to fatality of coronary events (44-
47). 
1.4.2 Other exposures  
1.4.2.1 Age  
Age at MI has been associated with increased MI/CHD fatality (3, 13, 15, 17). 
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1.4.2.2 Calendar year & early treatment 
The chain of survival is a series of steps performed shortly after a cardiac arrest (which 
includes CHD) occurring in order to increase the chances of survival of the person suffering 
such catastrophic event. These 4 steps are: 1) Early access; 2) Early cardiopulmonary 
resuscitation; 3) Early defibrillation and 4) Early advanced cardiac life support (48, 49). 
There are improvements over time regarding these steps in the last 10 years (48). The chain 
of survival was not considered in this thesis, because information about these steps is lacking 
for most of the subjects in our data. However, the chain of survival improves as the calendar 
years increase (48). Therefore, adjustment for calendar year is done in Study IV, but not for 
Studies II-III.  
1.4.2.3 Other factors 
A number of other factors have been studied in relation to MI/CHD fatality in population-
based studies. Physical inactivity has been associated with increased MI fatality (13). Lung 
volumes were studied in relation to MI fatality (13, 50): the forced expiratory volume in one 
second (FEV1) was inversely associated to CHD fatality in one study (50), but not in the 
another (13), and the forced vital capacity (FVC) was inversely associated with CHD fatality 
(50).  
Socioeconomic deprivation has been associated with increase fatality of MI events (51). 
Red distribution width (RDW) was associated with increased CHD fatality (52). Resting 
heart frequency had a tendency to be associated with increased CHD fatality (13). 
Birth weight has a U-shaped association with MI fatality in men, but not in women (53).   
1.5 METHODOLOGICAL CONSIDERATIONS 
1.5.1 Perspective I: MI/CHD fatality  
In what will be referred to as “perspective I” in this thesis, MI/CHD fatality is assessed in an 
inception cohort (9) of MI/CHD. Case fatality rate is defined as the proportion of cases that 
are fatal within a specified time (9). In Perspective I, we compare the case fatality rate among 
cases exposed to the variable of interest to the case fatality rate among the unexposed. 
This perspective, used in some population-based studies (13, 15, 17, 46), is shown in the top 
panel of Figure 3. 
This perspective is used in Studies II-IV. 
1.5.2 Perspective II: Risk of non-fatal MI and fatal CHD 
In what will be referred to as “perspective II”, the hazard ratio of non-fatal MI and fatal CHD, 
respectively, associated with the exposure of interest are assessed. If the point estimate for 
developing a fatal CHD is higher than the point estimate for developing a non-fatal MI, then 
it is inferred that the exposure of interest is associated to increased fatality of coronary events. 
This perspective has been used in several cohorts (44, 45, 54). The concept is illustrated in 
the bottom panel of Figure 3. 
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This perspective is used in Study IV, in parallel with Perspective I. 
 
Figure 3. Two different perspectives for assessing death shortly after an MI/CHD event.  
1.5.3 Validation of proxy-based information in MI cases 
In case-control studies of MI, fatal cases dying outside the hospital are usually not 
considered. Therefore, results generated from these studies can only be generalized to MI 
cases who survive long enough to be hospitalized. This is a disadvantage and the possibility 
to contact close relatives of the fatal cases, as “proxy respondents” may therefore be 
considered. One way to assess the validity of the information provided by “proxies”, used in 
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the present thesis (Study I) is to compare the odds ratios generated from a case-control study 
material when they are based on reports from the cases themselves (non-fatal cases) and 
when they are based on responses of proxies.  
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2 AIMS 
The main aim of this thesis is to contribute to fill the gap in knowledge regarding 
determinants of the fatality of coronary events. 
The specific aims of this thesis are: 
1. To increase knowledge regarding the validity of data collected from proxy respondents to 
MI cases. 
2. To assess how cardiometabolic risk factors (diabetes, hypertension, hyperlipidemia, 
overweight, and obesity), measured close in time to a first MI event, are associated with MI 
fatality. 
3. To increase knowledge about how presence of comorbidities may influence fatality in first 
time MI in the general adult population using an explorative approach. 
4. To assess sex specific associations between inflammatory markers and risk of a fatal 
outcome in subjects who subsequently experience a first coronary event. 
  9 
3 METHODS 
3.1 THE STUDY MATERIALS  
3.1.1 Stockholm Heart Epidemiology Program (SHEEP) (Studies I-III) 
3.1.1.1 Study base description 
SHEEP is a population-based case-control study. The study base comprises all Swedish 
citizens living in Stockholm, aged 45-70 years old free of previous hospitalizations with MI 
as a main or secondary diagnoses in Stockholm since 1975. The study period started on the 
13
th
 of January, 1992, and ended on the 12
th
 of January, 1994 in men and on the 31
st
 of 
December, 1994 in women. The upper age limit from the beginning of the study period until 
October 1992 was 65 years. Starting from November 1992, the age limit was raised up to 70 
years old.  
3.1.1.1.1 MI diagnostic criteria used in SHEEP and number of cases identified 
During the SHEEP study period, MI was diagnosed based on the following four diagnostic 
criteria stated by the “Coronary Units Care. Guidelines of treatment for Stockholm hospitals 
(in Swedish: Stockholm County Council. Hjärtintesivvård. Behandling for Danderyd 
skujhus, Ersta sjukhus, Huddinge sjukhust, etc… ) (55): 
1. Anamnesis, the patient must have any of the following:  
a. Crushing central chest pain with/without sweating in the last 24 hours before 
diagnosis with duration longer than 15 minutes that should not change with 
respiratory movements, changes in the body position or during ingestion. 
b. The previous symptom could last less than 15 minutes, if the patient was resting 
when it happened in the last 24 hours. 
c. Pulmonary oedema. 
d. Shock without suspicion of bleeding, hypovolemia, sepsis or intoxication. 
e. Syncope in the last 24 hours. 
2. Elevated enzyme values: 
a. Creatinin kinase (CK) levels over 3,3 µkat/L in men or over 2,5 µkat/L in women 
with CK-B values above 0,5 µkat/L. The quotient CK-B/CK must be 3-12%. The 
maximum value should be measured approximately between 15 and 18 hours 
before the symptoms onset. 
b. Two lactate dehydrogenase (LD) levels above 0,8 µkat/L with LD1 higher than 
3,3 µkat/L. The maximum value should be measured approximately between 36 
and 48 hours before the symptoms onset. 
3. A forthcoming pathological Q wave in at least two consecutive leads. 
4. Myocardial necrosis identified in an autopsy which an age that corresponds to the lapse 
between the onset of symptoms and the death. 
Individuals that had two out the first three criteria had an MI diagnosis. Individuals with the 
fourth criterion also had MI as a cause of death. These criteria were stated in 1990 and they 
did not change during the SHEEP study period.  
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From the study base, 2246 MI cases were identified from any of the following sources:  
1. Coronary units and internal medicine wards for acute care in Stockholm county.  
2. National Patient Registry: Cases with main or secondary diagnosis corresponding to 
MI (-International Classification of Diseases- ICD-9 410). 
3. Death certificates: Cases with ICD-9 codes 410 as a main or contributory cause of 
death were also identified. 
3.1.1.1.2 Definition of fatal MI and number of events identified (Studies II-III) 
MI cases who were hospitalized and died within 7 days after symptoms started or died 
without being hospitalized were classified as 7-day fatal MI (n=524). An alternative 
classification of fatal MI was used: 28-day fatal MI (n=603). 
3.1.1.1.3 Definition of non-fatal MI and number of cases identified. 
Study I included 243 participating 28-day non-fatal cases living with a spouse/common law 
spouse who received a questionnaire between 5th April, 1993 and 31st December, 1993.  
Cases who survived at least 28 days and filled in the questionnaire were included in Studies II 
and III as non-fatal MI cases (n= 1,381). In Study III cases who survived 7 days but died 
within 28 days were also considered non-fatal (n=79), while in Study II these cases were 
excluded from the analyses. 
3.1.1.1.4 Proxy respondents (Study I) 
The SHEEP secretariat sent an invitation letter to participate in a pilot validation study to a 
selection of the MI cases participating in SHEEP and asked for permission to contact his/her 
spouse/common law spouse (“proxy”). If the case agreed to participate, the SHEEP 
secretariat sent a similar letter to the proxy. The proxies who agreed to participate (n=243) 
were asked to complete a very similar questionnaire to the one sent to the MI patients. When 
the data collection had ended, the proxies were sent a letter where they were asked about 
whether some parts of the questionnaire were difficult to answer and if they received any help 
from their spouses. None of the proxies reported they received help from their spouses. 
However, 5 reported they had some difficulty giving information about work related 
exposures. 
3.1.1.1.5 Control individuals (Study I) 
Control individuals were selected continuously from the population register during the study 
period. Each control was matched to the respective case index by sex, age (within 5 years) 
and residential area. Matched controls were selected within 2 days after his/her respective 
index case occurrence. The first responding matched control to each selected case was 
included.  
The extraction of participants from the SHEEP (for Studies I-III) is shown in Figure 4. 
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Figure 4. Participants in SHEEP (Studies I-III) 
3.1.1.2 Questionnaire data  
3.1.1.2.1 Use of the questionnaire data in the validation study (Study I) 
The exposure assessment in Study I was exclusively based on questionnaire data provided by 
proxies, cases and controls (except for age and sex).  
The participants were asked to report how often (considering the previous year) they had the 
following sleep-related problems: 1) Difficulties to fall asleep, 2) Difficulties to wake up, 3) 
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Difficulty to go back to sleep, 4) Heavy snoring, 5) Nightmares, 6) Not feeling thoroughly 
rested after waking up, 7) Waking up too early, 8) Restless while sleeping, 9) Feeling 
tired/sleepy, 10) Eyes tired/irritated, 11) Experiencing non-voluntary falling asleep at 
workplace, 12) Experiencing non-voluntary periods of sleep during leisure time. 13) Feeling 
fatigued and easily distracted. 
For each sleeping problem item, there were five predefined answer alternatives: “never”, “a 
few occasions yearly”, “a few occasions monthly”, “a few occasions weekly” and “on daily 
basis”. The median frequency of sleeping problems among control individuals was 
determined and subjects reporting a frequency of problems at that median level or above were 
classified as exposed; for all sleeping-related problems except from “Experiencing non-
voluntary periods of sleep during leisure time”, the answer alternative “a few occasions 
monthly” was the median. For “Experiencing non-voluntary periods of sleep during leisure 
time”, it was “a few occasions yearly”. 
The definition of “leisure time physical inactivity” was based on reports of questions 
regarding the level of leisure time physical activity in the previous 5 to 10 years. Respondents 
reporting “very little exercise” or “isolated walks only” were considered exposed. The 
reference category for this study includes a combination of those respondents who replied 
either “regular exercise” (at least once weekly) or “exercise once in a while” 
The participants were also asked about other variables that include diet, alcohol consumption, 
work-related exposures and psychosocial factors. The validity of responses in proxies was 
evaluated for these variables. 
3.1.1.2.2 Definition of variables (Studies I-III) 
Participants were considered exposed to hypertension if they replied “yes” to the query “do 
you have hypertension?”/”does your close relative have hypertension?”, or if they reported 
use of any medication against hypertension. Identification of exposure to diabetes and 
hyperlipidemia, respectively, was done in a similar fashion.  
The questionnaire included specific questions on previous diagnoses of history of heart 
failure, stroke, angina or intermittent claudication. In addition, any pharmacological treatment 
during the week preceding the MI event was asked for and also the reason for any treatment 
(Studies II-III). Cases were considered “exposed” or “unexposed” to each comorbidity 
according to the responses to these questions. “Previous non-MI CVD” was defined from 
questionnaire reports by the participant/proxy of previous diagnosis of heart failure, stroke, 
angina or intermittent claudication (Studies I). 
The body mass index (BMI) was calculated based on questionnaire information on weight 
and height. However, if these data were available from the physical examination (non-fatal 
cases) or from autopsy reports (fatal cases), they were used from these other sources instead 
(Studies II-III). “Overweight” was defined as a BMI ≥ 25 kg/m2 and < 30 kg/m2. “Obesity” 
was defined as a BMI ≥ 30 kg/m2.  
Individuals reporting current smoking of cigarettes, cigarillos, cigars or pipes for at least a 
year, or that they had quit smoking within the last two years, were classified as current 
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smokers (Study I-II). Stopping smoking more than two years ago was classified as former 
smoking (Study I). Not smoking in a regular fashion for at least a year was classified as 
“never-smoking” (Study I-II). The use of moist snuff or Swedish tobacco in the year 
preceding the survey was classified as use of “smokeless tobacco” (contrary to “non-use”) 
(Study I). 
Based on replies to questions with preset options about cardiovascular diagnoses and causes 
of death (whether relevant) in either a parent and/or a sibling of the index participant before 
they turned 65 years old, participants were classified as exposed or non-exposed to maternal, 
paternal and sibling history of CHD and CVD, respectively (Studies I-II). In these 
classifications, CHD comprised “sudden death”, “MI” and “angina” whereas CVD comprised 
CHD and stroke. A “Don’t know” reply was included as a predefined answer choice. Our 
analyses used two distinct methods: A) Using individuals who provided complete data about 
history of disease and cause of death (if relevant) in parents and potential siblings. B) 
Considering individuals who provided any information about history of disease or cause of 
death (if relevant) in parents or potential siblings. In approach B, “don’t know” answers were 
set to “no” (Study I).  
3.1.1.3 Register based data on comorbidities (Studies II-III) 
Data from questionnaires were used to assess presence of cardiometabolic risk factors 
(usually comorbidities) and comorbidities in Studies II and III. However, the comorbidities of 
interest were also considered present if they were registered in any of the following: the 
Swedish National Patient Register (NPR), the Cause of Death Register (CDR) (Study II-III) 
and the autopsy reports (Study III).  
3.1.1.3.1 The Swedish National Patient Register (NPR) (Studies II-III) 
The NPR contains data on the date of admission, the date of discharge and the main and 
secondary diagnoses of each hospitalization occurring in Swedish hospitals. Data from the 
NPR, complete in Stockholm County since 1975 and nationwide since 1987, were available 
for all MI cases included in the SHEEP (56). Both main and secondary diagnoses (up to 7 
secondary diagnoses) were considered to assess the presence of cardiometabolic risk factors 
(Study II) and comorbidities (Study III).  
For each individual, the number of hospitalizations during the ten years preceding the MI 
event was counted using the NPR, but hospitalizations due to normal child delivery were not 
considered. Individuals were divided in 4 categories: not hospitalized (reference category), 
one hospitalization, two hospitalizations, and three or more hospitalizations (Study III).  
For the study period, the NPR contains information on the 8
th
 (1969-1986) and the 9
th
 (1987-
1996) revisions of the ICD. The ICD revisions contained in the NPR used for Study IV are 
described in 3.1.2.2.1. 
3.1.1.3.2 The Cause of Death Register (CDR) (Studies II-III) 
The CDR contains a copy of the information registered in each death certificate of deaths 
occurring in Sweden. It covers all people holding a permanent residency in Sweden and who 
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died within the study period. The variables of this register include the unique personal 
identification number, age, sex, date of death, the main and secondary causes of death, the 
manner of death, the timing between the beginning of symptoms and death, and on which 
grounds the causes of death were ascertained. 
For the study period, the CDR contains information based on the 9
th
 (1987-1996) revision of 
the ICD (57). The ICD revisions contained in the CDR used for Study IV are described in 
3.1.2.2.2. 
3.1.1.3.3 Autopsy records (Studies II-III) 
Among 7-day fatal cases identified in the inception cohort extracted from SHEEP, 72% 
(n=377) underwent autopsy, as documented in death certificates, and 23% (n=120) did not. 
The MI diagnosis in the latter group was asserted on clinical grounds.  
Among the fatal cases who underwent autopsy, 49% (n=186) of the reports were retrieved 
from county council archives (mainly for Stockholm County) or from departments of forensic 
medicine (all in Stockholm, except from one autopsy that took place in Uppsala). Among the 
autopsies for which a report was retrieved, 37% were performed at a department of forensic 
pathology.  
An historical summary was available in 95% of the retrieved autopsy reports, and this 
information was used to identify comorbidities in fatal cases for which questionnaire data 
were not available. In addition to the data extracted from the SHEEP questionnaire and from 
the NPR, data from the historical summary was used to identify comorbidities (Study III). 
The findings from the external and internal autopsy examinations were reviewed for 
indicators of additional findings indicating comorbidity in a structured manner (Study III). 
3.1.1.3.4 The longitudinal integration database for health insurance and labor market 
studies (LISA) (Studies II-III) 
Data on individual disposable income the year preceding the year of the index event was 
extracted from the LISA register as an indicator of socioeconomic status. 
3.1.2 Apolipoprotein-related Mortality Risk (AMORIS) cohort (Study IV) 
3.1.2.1 Study base description 
Study IV is based on the AMORIS cohort described in extenso in previous publications (58-
60). In brief, the cohort comprises male and female participants who previously went through 
a health check-up, with samples analyzed by the Central Automation Laboratory (CALAB) in 
Stockholm, Sweden between 1985 and 1996.  
The AMORIS cohort includes 391,669 male and 412,077 female participants of all ages with 
varying information on a large number of biomedical factors (60). In Study IV, a minimum 
age at baseline was set to 18 years old. 
3.1.2.2 Low-grade inflammation biomarkers  
All laboratory measurements were extracted from the CALAB dataset in AMORIS.  
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In Study IV low-grade inflammation was evaluated using a score comprised by five 
biomarkers. The five biomarkers used were: C-reactive protein (CRP), haptoglobin, white 
blood cell counts (WBC), albumin and uric acid. Three of them are acute phase proteins 
(APPs; CRP, haptoglobin and albumin), whereas WBC represents inflammatory cells and 
uric acid is a DAMP. 
Sex specific distributions of the individual biomarkers forming basis for the inflammation 
score were analysed. The sex specific quartile cut-off values were identified and shown in 
Table 1. For each biomarker value in the top quartile, a point was generated in the 
inflammation score, except for albumin where a point was generated if the value of this 
biomarker was in the bottom quartile.  
Table 1. Sex specific cut-off values to generate a point in the inflammation score 
 Men Women 
Serum CRP ≥ 7.0 mg /L ≥ 7.0 mg /L 
Serum haptoglobin ≥ 1.3 g/L ≥ 1.2 g/L 
WBC ≥ 7.5 x 109/L ≥ 7.6 x 109/L 
Serum uric acid ≥ 360 mmol/L ≥ 278 mmol/L 
Serum albumin ≤ 42 g/L ≤ 41 g/L 
CRP: C- reactive protein; WBC: White blood cell count. 
Laboratory methods for the biomarkers used in the inflammation score and additional 
biomarkers has been earlier described (61-64). 
Only subjects with valid information on each of the biomarkers forming the score were 
included in Study IV (Figure 5). 
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Figure 5. Selection of the study sample from the AMORIS cohort (Study IV) 
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3.1.2.3 Registers linked to AMORIS cohort data 
3.1.2.3.1 The NPR 
This register has been described in section 3.1.1.3.1. 
For the study period, the NPR contains information of the 8
th
 (1969-1986), 9
th
 (1987-1996) 
and 10
th
 (since 1997) revisions of the ICD (57). 
3.1.2.3.2 The CDR  
This register has been described in section 3.1.1.3.2. 
For the study period, the CDR contains information of the  9
th
 (1987-1996) and 10
th
 (since 
1997), revision of the ICD (57). 
3.1.2.4 CHD case identification in AMORIS 
3.1.2.4.1 CHD diagnostic criteria 
The diagnostic criteria among hospitalized MI cases have changed during the AMORIS 
follow-up. The diagnostic criteria until 2000 are the same as those used in SHEEP, described 
in 3.1.1.1.1. 
3.1.2.4.1.1  CRITERIA FOR DETECTIN G FIRST TIME MI  USED SINCE 2000  (18):  
1. Detection of a rise and/or fall of cardiac biomarker values (preferably cardiac 
troponin) with at least one of the following: 
  ○ Symptoms of ischemia. 
  ○ New or presumed new significant ST-segment-T wave (ST-T) changes or new left 
bundle branch block. 
  ○ Development of pathological Q waves in the ECG. 
  ○ Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality. 
  ○ Identification of an intracoronary thrombus by angiography or autopsy. 
2. Cardiac death with symptoms suggestive of myocardial ischemia and presumed new 
ischemic ECG changes or new left bundle branch block, but death occurred before 
cardiac biomarkers were obtained, or before biomarker values would be increased. 
3.1.2.4.2 Non-fatal MI 
Non-fatal cases were identified from the NPR if they were hospitalized with MI (ICD-9 410 
or ICD-10 I21) as a main diagnosis or secondary diagnosis during the follow-up and survived 
at least 1 day after being hospitalized.  
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Cases with MI as a main or secondary diagnosis in the NPR before the first examination in 
AMORIS were excluded (n=8,419). After excluding these subjects, as well as additional 
exclusions, the numbers of participants with complete information of all biomarkers were 
43,948 men and 58,766 women (Figure 5). 
3.1.2.4.3 Fatal CHD 
Fatal CHD cases were defined as those who were hospitalized with MI (ICD-9 410 or ICD-
10 I21) as a main diagnosis or any secondary diagnosis and died in the first day (regardless of 
the cause of death), and those participants who died out of hospital with CHD (ICD-9 410-4 
or ICD-10 I20-5) as an underlying or cause of death without previous hospitalizations with 
MI. An alternative definition of fatal CHD included death up to 28 days 
3.1.2.5 Possible confounders 
3.1.2.5.1 Diabetes 
Subjects were classified as suffering diabetes if any of four conditions occur before the index 
examination: 1) fasting serum glucose level above 6.9 mmol/L, 2) glycosylated hemoglobin 
(HbA1C) ≥ 6.5%, 3) a documented hospitalization in the NPR with diabetes as main or 
secondary diagnosis (ICD 9 code 250; ICD10 codes E10-E13), and 4) a registration in the 
Swedish National Diabetes Register.   
3.1.2.5.2 Angina 
Diagnoses of angina prior to the index examination were identified from the NPR, diagnostic 
code (main or secondary diagnosis) ICD-9 code 413 or ICD-10 code I20. 
3.1.2.5.3 Highest attained education 
The highest attained level of education was used as an indicator of socioeconomic status. The 
information was extracted from LISA national register for the year 1990 if the index 
examination took place before 1993 and for the year 1995 if it took place 1993 or later. 
The educational level was categorized into four levels: nine years or less; ten to twelve years; 
thirteen years or more; and missing (65).  
3.1.2.5.4 Other laboratory measurements 
Others biomarkers extracted from AMORIS as additional variables include fasting glucose 
levels, HbA1C, total cholesterol and triglycerides. Laboratory methods to assess these 
biomarkers were described in earlier publications (63, 64). 
3.2 STATISTICAL ANALYSES 
3.2.1 Assessing Proxy Bias (Study I) 
The prevalence of each exposure according to data collected from cases, proxies, and controls 
was calculated. To assess possible bias introduced by the use of data collected from proxies 
instead of cases, two odds ratios (ORs) were calculated using conditional logistic regression: 
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1) OR-A from a model based on data collected from cases and their matched controls, and 2) 
OR-B from a model based on data collected from the proxies and the same set of controls. 
For each exposure, the quotient from dividing OR-B by OR-A was calculated (“proxy bias”). 
 
A proxy bias of 1.0 indicates that on average proxies do not systematically overestimate or 
underestimate the exposure assessed as compared to cases. Values below 1.0 indicate that 
proxies underestimate the exposure and that OR-B is underestimated, whereas values above 
1.0 indicate that proxies overestimate the exposure and that OR-B is overestimated. The 95% 
CI limits for the “proxy bias” was calculated using resampling bootstrap based on 5000 
iterations, considering the difference between the variable coefficients of the model 
producing OR-A and OR-B. The bootstrap is suitable because it requires very limited 
assumptions about the probability distribution where the data comes from. Logistic 
regressions and the bootstrap analyses were performed using SAS version 9.2. This method 
to assess disagreement between cases and proxies has not earlier been used, as far as the 
literature currently states.  
3.2.2 Assessing MI fatality (Studies II-III) 
Using the NPR and data from the SHEEP questionnaire, the prevalence of all comorbidities 
in the group who suffered a fatal MI was assessed (Study III). Whenever questionnaire data 
were not available for a fatal case, the historical summary in the autopsy report, if available, 
was used instead. A few of the comorbidities considered, such as asthma, were defined 
narrowly and identified with a single ICD-8/ICD-9 code whereas the majority, including 
psychiatric disease was not. 
 
The risk of death within 7 days among cases (7-day MI fatality) was calculated in different 
strata of cardiometabolic risk factor status(diabetes, hypertension, hyperlipidemia, and BMI 
categories) (Study II), number of hospitalizations, and comorbidities with prevalence above 
2% in fatal MI cases (Study III).  Risk ratios with 95% CIs of 7-day MI fatality associated 
with the different risk factors were calculated using binomial regression with log link.  
 
Adjustments were made for age and sex in all analyses (Studies II-III), except for alcoholism 
and epilepsy (Study III). In subsequent analyses, additional potential confounding factors 
were considered for adjustments: cardiometabolic risk factors (other than the one under 
study), current smoking, physical inactivity, educational level, low disposable income, family 
history of CVD, parental history of premature cardiac death, and number of hospitalizations 
(Study II). All confounding variables were dichotomized, except BMI and educational level 
that were divided into four and three categories, respectively (Study II). Because the results 
from Study I showed an overestimation of level of physical inactivity by proxies, this variable 
was not considered in the adjustments (Study II).  
 
The attributable proportion (AP) of each comorbidity (AP) was calculated using the 
following formula: 
AP=
𝑅𝑅−1
𝑅𝑅
∗ 𝑝𝑟𝑜𝑝𝑜𝑟𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 7 − 𝑑𝑎𝑦 𝑓𝑎𝑡𝑎𝑙 𝑐𝑎𝑠𝑒𝑠 𝑤𝑖𝑡ℎ 𝑡ℎ𝑖𝑠 𝑐𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑦 
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3.2.3 Low-grade inflammation in relation to risk of non-fatal MI, fatal CHD 
and a fatal outcome of future coronary events (Study IV) 
3.2.3.1 Incidence rates of non-fatal MI and fatal CHD  
Incidence rates of non-fatal MI and fatal CHD, stratified by sex and inflammation score were 
calculated. Sex specific hazard ratios (HR) with 95% CI of non-fatal MI and fatal CHD, 
respectively, associated with a one-unit increase of the inflammation score were modelled 
using Cox regression. Analyses using the score as a categorical variable with zero as 
reference were also performed. Follow up started at baseline and ended at time of the event, 
death from other cause or end of follow-up, whichever occurred first. Factors considered for 
adjustments were age at baseline, diabetes, educational level, serum total cholesterol level, 
serum triglyceride level and angina.  
3.2.3.2 Case-fatality of future coronary events 
The association between a one-unit increase of the inflammation score and 1-day and 28-day 
fatality of coronary events, respectively, was modelled using logistic regression. Analyses 
using the inflammation score as a categorical variable with zero as reference were also 
performed. Adjustments were made for age at the index event and calendar year of index 
event. In additional models, further adjustments were made for diabetes, educational level, 
total cholesterol, triglycerides and angina.  
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4 SUMMARY OF THE RESULTS 
4.1 VALIDITY OF INFORMATION FROM PROXY RESPONDENTS (STUDY I) 
The main finding of the validation study is the agreement between index MI cases and their 
respective spouses and common-law spouses for most of the exposures under study. 
However, as compared to their index cases, proxies had a tendency to overestimate the 
exposure to leisure time physical inactivity, non-voluntary falling asleep during leisure time, 
and heavy snoring. In the other hand, as compared to index cases, proxies had a tendency to 
underestimate the frequency of non-voluntary falling asleep at work, pollution at workplace, 
coffee consumption and intake of vitamin supplements. 
4.2 RISK FACTORS ASSOCIATED TO FATALITY OF CORONARY EVENTS 
(STUDIES II-IV) 
4.2.1 Association between cardiometabolic risk factors and MI fatality 
(Study II) 
Diabetes was associated with an increased risk of dying within 7 days after the MI (RR 1.68, 
95% CI 1.20-2.28) both in crude and multiple adjusted models.  
Overweight, as compared to normal weight, was associated with a decreased risk of dying 
within 7 days after the MI (RR 0.68, 95% CI 0.49-0.94). For obesity, also compared to 
normal weight, a similar tendency was observed.  
The risk ratios of 7-day MI fatality associated with hyperlipidemia and hypertension, 
respectively, were close to the null. 
4.2.2 Comorbidities in relation to MI fatality (Study III) 
4.2.2.1 Association between the number of previous hospitalizations and MI fatality 
Fatal cases were more often repeatedly hospitalized prior to the MI event. As the number of 
hospitalizations increases, the stronger the association with MI fatality becomes.  
4.2.2.2 Prevalence of specific comorbidities in fatal MI cases 
The five most common comorbidities among 7-day fatal cases were all related to CVD: 
hyperlipidemia (36.1%), hypertension (35.3%), angina (34.7%), diabetes (23.7%) and heart 
failure (18.4%). The six comorbidities most strongly associated to 7-day MI fatality were 
epilepsy (RR 2.4, 95% CI 1.7-3.0), heart failure (RR 2.0, 95% CI 1.7-2.4), alcoholism (RR 
2.0, 95% CI 1.9-3.2), stroke (RR 1.9, 95% CI 1.6-2.6), renal diseases (RR 1.8, 95% CI 1.4-
2.2) and cancer (RR 1.8, 95% CI 1.4-2.2). The comorbidities found to have the highest 
estimated AP were: heart failure (9%), diabetes (7%), stroke (7%), psychiatric disease (other 
than alcoholism) (5%) and alcoholism (5%). Intermittent claudication, hyperlipidemia, 
hypertension, angina and obesity were not associated with 7-day fatality of MI. 
Table 2 shows the findings from our structured review of the external and internal 
examination parts of the autopsy reports, indicative of the presence of comorbidities. The 
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most prevalent indicators of comorbidity in the external examination were missing teeth 
(considered to be an indicator of dental disease), obesity and underweight. The internal 
examination revealed myocardial scars (indicative of a previous silent MI), severe 
atherosclerosis of the abdominal aorta, and hepatic steatosis. Half of the fatal cases with 
moderate-severe atherosclerosis of the abdominal aorta had no previous record of CVD in 
any of our other sources of information. Fifty percent of those with hepatic steatosis exhibited 
no evidence of alcoholism, hospitalizations for alcohol psychosis or use of medications for 
treatment of alcohol abuse.  
Table 2. Findings indicative of the presence of comorbidity in 7-day fatal MI cases 
based solely on the autopsy reports.  
Autopsy finding All  N 
External examination, N (%)   
Missing teeth 27 (38.6) 68 
Obesity 12 (13.6) 88 
Underweight 6 (6.8) 88 
   
Internal examination, N (%)   
Abdominal aortic atherosclerosisa   
        More advanced than individuals of the same age 136 (76.4) 178 
        Low degree 22 (12.4) 178 
        Moderate degree 60 (33.7) 178 
        Severe degree 54 (30.3) 178 
        Difficult to assess by the pathologist or not described 11 (6.2) 178 
Myocardial scar 68 (36.6) 186 
Hepatic steatosis 51 (28.0) 185 
MI: myocardial infarction; NA: Not available; obesity was defined as a body mass index of 30 kg/m2 or more; underweight 
was defined as a body mass index of 18 kg/m2 or less; 
aAs described by the pathologist in the autopsy protocol. 
4.2.3 Low-grade inflammation and fatality of future coronary events (Study 
IV) 
4.2.3.1 Non-fatal MI and fatal coronary events 
The mean period of follow-up was 22.1 ± 5.8 years. The number of incident CHD cases 
identified during follow-up, forming basis for the analyses of case fatality, was 4,913 in men 
and 4,017 in women. Of them, 1,357 male cases (28%) and 1,347 female cases (34%) were 
classified as 1-day fatal. Among the fatal coronary events, 2,408 (1,218 men and 1,190 
women) occurred out-of-hospital or at the hospital upon arrival (with no admission 
diagnosis). Of these, 47% (57% of the men and 36% of the women) were subject to autopsy; 
another 34% were subject to clinical investigation at the hospital prior to death; and an 
additional 10% to clinical investigation outside of the hospital prior to death.   
Among the individuals who suffered a fatal coronary event during the follow-up, the mean 
age at the time of this event was 73 years for men and 81 years for women (Table 3). The 
corresponding ages at the time of a non-fatal coronary event were 69 years and 76 years 
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(Table 3). The average time that elapsed between the examination and the coronary event was 
13.3 ± 6.3 years.  
Table 3. Age and distribution of biomarkers conforming the inflammation score in 
participants in the AMORIS cohort who subsequently suffered a coronary event during 
follow-up. 
 Men Women 
 1-day fatal CHD 
(N=1,357) 
Non-fatal MI 
(N=3,552) 
1-day fatal CHD 
(N=1,347) 
Non-fatal MI 
(N=2,670) 
Age, years (mean ± SD) 60 ± 13 56 ± 12 68 ± 11 62 ± 12 
Age at coronary event, years (mean ± SD) 73 ± 11 69 ± 11 81 ± 10 76 ± 11 
     
Serum levels of the inflammatory markers     
   CRP (mg/L), median (IQR) 4 (1-9) 4 (1-8)  4 (1-10) 4 (1-8) 
   Haptoglobin (g/L), mean ± SD 1.23 ± 0.44 1.18 ± 0.38 1.24 ± 0.41 1.19 ± 0.37 
   WBC  (n x 109/L), median (IQR) 6.9 (5.8-8.5) 6.7 (5.6-8.2) 6.7 (5.6-8.2) 6.6 (5.4-8.0) 
   Uric acid (mmol/L), mean ± SD 340 ± 78 334 ± 70  290 ± 80 282 ± 74 
   Albumin (g/L), mean ± SD 42.0 ± 3.0  42.0 ± 3.0 41.0 ± 2.7 41.4 ± 2.6 
CHD: coronary heart disease; MI: myocardial infarction; SD: Standard deviation; CPR: C-reactive protein; IQR: Interquartile 
range; WBC: white blood cell count. 
4.2.3.2 Associations between the inflammation score and non-fatal MI, fatal CHD and 
fatality of future coronary events 
The sex stratified incidence of fatal CHD and non-fatal MI, respectively, rose by 
inflammation score. A significant association with non-fatal MI and fatal CHD, respectively, 
was observed for each unit increase in the inflammation score in both the crude and the 
adjusted models. This association was somewhat more pronounced for fatal CHD (adjusted 
models: HR in men 1.36, 95% CI 1.30-1.42; HR in women 1.34, 95% CI 1.28-1.40) than for 
non-fatal MI (adjusted models:  HR in men 1.23, 95% CI 1.19-1.25; HR in women 1.25, 95% 
CI 1.21-1.29). 
In men, the crude OR for 1-day and 28-day fatality of coronary events, respectively, 
associated with a one-unit increase in the inflammation score were 1.17 (95% CI 1.11-1.23) 
and 1.18 (95% CI 1.12-1.24), respectively. These values decreased to 1.13 (95% CI 1.07-
1.19) and 1.13 (95% CI 1.07-1.19) after adjustments for age at the time of the coronary event 
and calendar year of this event. Further adjustments for diabetes, level of education, serum 
levels of total cholesterol and triglycerides, and angina did not substantially alter these values. 
In women, the crude OR for 1-day and 28-day fatality of coronary events, respectively, 
associated with a one-unit increase in the inflammation score were 1.16 (95% CI 1.01-1.23) 
and 1.16 (95% CI 1.10-1.22), respectively. These values decreased to 1.12 (95% CI 1.06-
1.19) and 1.12 (95% CI 1.06-1.18) after adjustment for age at the time of the coronary event 
and calendar year of this event. As for the men, further adjustment for diabetes, level of 
education, serum levels of total cholesterol and triglycerides, and angina had little impact in 
the estimates.  
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5 DISCUSSION OF RESULTS 
5.1 VALIDITY OF INFORMATION FROM PROXY RESPONDENTS (STUDY I) 
Taken together, the results of Study I suggest that information collected from close relatives 
of MI patients regarding their exposures prior to the MI event in general is valid.  Caution 
must however be taken in relation to information on level of physical activity, presence of 
sleep-related disorders as well as some work-related exposures.  
The overestimation observed for level of physical inactivity agrees with a study by Nelson et 
al. (66) based on index patients who suffered a stroke.  
5.2 POTENTIAL DETERMINANTS OF CORONARY EVENT FATALITY 
(STUDIES II-IV) 
The interpretations of results on associations between risk factors and fatality of coronary 
events are not straight-forward from a disease etiology perspective. In an inception cohort of 
individuals who suffered an MI, extracted from a case-control study material, as in Studies II 
and III, the exposures are assessed close in time to the MI event. Both the current exposure 
status and the duration of the exposure back in time may affect the outcome of the MI event. 
In an inception cohort extracted from a population-based cohort, as in Study IV and several 
other studies (13, 14, 34), the exposures are generally assessed distant in time from the 
disease onset. In neither of those study designs, it is possible to distinguish between 
influences from exposures during the period before the MI event from influences during the 
acute phase of the event. The same exposure factor may theoretically exert effects both before 
the MI event and during the acute phase. The pre-event influences may theoretically 
influence not only if the MI event will occur or not, but also the severity of the event. This is 
illustrated in Figure 6. 
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Figure 6. The timing when the exposure exerts its effect cannot be asserted regardless the 
study design.  
5.3 POSSIBLE MECHANISMS IN RELATION TO CARDIOMETABOLIC RISK 
FACTORS ASSOCIATED TO MI FATALITY (STUDY II) 
5.3.1 Diabetes  
Our finding of an association between diabetes and MI fatality agrees with findings from two 
previous publications where both hospitalized patients and out-of-hospital deaths were 
considered (15, 32). This finding also agrees with a large body of literature reporting such 
association in studies restricted to hospitalized patients (29, 30, 35, 67, 68). 
Possible mechanisms explaining why diabetes increases MI fatality are related to decreased 
blood supply in normal and infarcted myocardial tissue as compared to persons without 
diabetes  (69). Animal models show a decreased availability of nitric oxide in diabetic mice, 
leading to a fatal vasoconstriction (70). Another possible mechanism relates to a reduced 
consumption of glucose by the myocyte due to a decreased translocation of glucose 
transporter 4 (GLUT4) to the sarcoplasmic membrane (69). Yet another possible mechanism 
is the decreased angina perception that leads to decreased awareness of MI which may render 
it fatal due to a delay in seeking care. Silent MI is more common in individuals with diabetes 
(71) and scarred tissue in the heart may negatively influence the recovery of function of the 
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heart in the acute phase of an MI event.  We identified signs of a previous silent MI in 36.6% 
of the fatal cases subjected to autopsy in SHEEP. However, because we had no possibility to 
assess silent MI in non-fatal cases, we could not assess the association between silent MI and 
MI fatality.    
Future research on how diabetes may influence MI fatality may perhaps take advantage of 
post mortem vitreous glucose level measurements mirroring serum glucose levels just before 
death (72).  
5.3.2 Overweight, obesity, hypertension and hyperlipidemia 
Results regarding overweight and obesity, showing an inverse relation with MI fatality agree 
with previous studies of hospitalized MI cases (40, 73).  However, a study where out-of-
hospital deaths are included showed no association (14). A possible reason for this 
discrepancy is that BMI were categorized while the compared study assessed BMI as 
continuous. Since there is no clear understanding about possible biological mechanisms, our 
results must be interpreted with caution. 
Our results are coherent with the “obesity paradox”, a hypothesis stating that individuals with 
a high BMI have a better prognosis after a CVD (74, 75). From a biological perspective, our 
observed low 7-day MI fatality in overweight and obese individuals, as compared to normal 
BMI, could be attributed to larger fat storages than in thinner peers which lead to more 
energy available to engage the demands after an MI event takes place. Another explanation of 
our findings might be that individuals with normal weight may have comorbidities that made 
them lose weight rendering them vulnerable after an MI occurs (76). Despite adjustments for 
comorbidities in the final models, there is a possibility that residual confounding effects exist. 
For instance, insulin resistance as well as complicated diabetes may involve weight loss and 
may be associated with MI fatality. 
Hypertension and hyperlipidemia for example are known to be associated with an increased 
incidence of MI, but in Studies II and III, they were not associated with MI fatality. These 
results could however also potentially be explained by presence of the so called “index event 
bias”. An author states that “Index event bias is an unwelcome consequence of selecting a 
study population on the basis of a prior event. The possibility of index event bias should be a 
reason for caution in the causal interpretation of (null) associations, because it can conceal the 
effect of risk factors” (77). This explanation is not widely accepted, for example, in an 
editorial from the European Heart Journal, it is stated that the effect of obesity and 
overweight on patient suffering CVD is real, because some comorbidities can decrease the 
weight and increase death in these patients (76).  
5.4 POSSIBLE MECHANISMS BEHIND THE ASSOCIATIONS BETWEEN 
FATALITY OF CORONARY EVENTS AND INFLAMMATION AND VARIOUS 
COMORBIDITIES (STUDIES III-IV) 
5.4.1 Inflammation 
Inflammation is a non-specific immune response to any kind of injury (78). Low-grade 
inflammation could be considered as an inflammatory response in absence of inflammation 
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cardinal focal symptoms and signs, known as the Celsus tetrad (warmth, pain, redness and 
swelling). As our results point out, low-level inflammation might increase fatality after a 
future coronary event. Possible mechanisms proposed include a decreased buffering capacity 
to engage the coronary event due to a more diffuse necrosis (16) or an increased possibility of 
developing a fatal arrhythmia (16, 17, 79).  
It is not difficult to speculate that chronic symptomatic inflammation will also favor a deadly 
outcome after a coronary event with similar mechanisms. All of the diseases identified in 
Study III to be associated to increased MI fatality have a symptomatic inflammatory 
component, with the exception of psychiatric disease and epilepsy. However, low-grade 
inflammation seems to be associated to psychiatric disease (80) unless it is related to an 
organic component, for example, drug abuse or some dementias when a symptomatic 
inflammation might occur. 
Regardless the clinical presentation of inflammation, the timing of its effect on the MI/CHD 
event cannot be easily assessed as we mentioned above in 5.2.   
5.4.2 Number of hospitalizations 
In the inception cohort of MI cases extracted from SHEEP, the number of previous 
hospitalizations was associated with increased MI fatality after adjustment for age, sex and 
low disposable income (Study III). Such association was previously not analyzed. The 
number of hospitalizations might reflect multiple co-morbidities, severe comorbidity or the 
amount of damage to organs which in turn may affect survival in the acute phase of a MI 
through an increased fragility (unspecified). Another possibility is that the number of 
hospitalizations reflect, potential deleterious effects of various treatments hampering the 
chances of survival in the event of an MI. The  number of hospitalizations may also perhaps 
reflect the level of anxiety related to deteriorating well-being and/or stress from being absent 
from work and not being able to take care of private matters, which might influence MI 
fatality via mechanisms that are as yet unknown.  
5.5 GENERALIZABILITY OF RESULTS (STUDY II-IV) 
The results based on the SHEEP material, collected between 1992 and 1994 could be difficult 
to be generalized to more recent settings, considering that the criteria for MI diagnosis has 
changed (18, 55) and that treatments for specific diseases and exposures have improved over 
time. 
AMORIS is a very large cohort of men and women living in Stockholm county comprising 
almost a half of the population in this county (60).  However, the generalizability of results to 
the general population may be somewhat compromised due to a potential “healthy worker” 
effect (a selection of individuals healthier than the general population, the underlying reason 
being that they are employed and thus not too sick to be in the working force) (81).  The 
mortality rate in this cohort is somewhat lower than the mortality rate in general Stockholm 
population (standardized mortality rate: 0.86) (60).  
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6 DISCUSSION OF METHODS 
6.1 DESIGN LIMITATIONS OF THE VALIDATION STUDY (STUDY I) 
The main limitation of this study design is a potential misclassification of the exposure in 
either the case or the control or in both. Because the design builds upon a “true” odds ratio 
based on reports from cases and controls, the assessment of proxy data will not be correct if 
the compared odds ratio is not “true”. The study design of Study I cannot address the 
occurrence of such misclassification.  A comparison to objective measures in the cases would 
have been preferable but for most exposures considered such data would not be possible to 
get.  
6.2 POSTMORTEM MI ASSESSMENT 
An advantage of the SHEEP study is the thorough assessments of MI as a cause of death 
performed by clinicians based on data from death certificates. The relatively high rate of 
autopsies during the 1990’s when the study was performed contributes to a high validity of 
postmortem MI assessment. Problems to distinguish between MI death and other cardiac 
related death may however still have been present.    
It is for example not possible to ascertain MI if the death occurs too early for signs of MI to 
be detected using light microscopy or the naked eye as described in 1.3. The Multinational 
Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) consortium 
refers to these cases as F2 (82), and White et al. called them “MI type 2” in their updated MI 
criteria (18). 
Due to the problems to distinguish MI death from other cardiac related death, most studies 
use the broader “CHD death” definition instead of MI death. In Study IV, we chose to do so 
because we had no access to autopsy records. Further, the declining rate of autopsies since the 
1990’s may have led to an attenuated validity of post mortem MI assessment. 
Because the proportion of autopsies has decreased over time in Sweden as shown in Figure 8, 
it might be intuitive to think that the proportion of autopsies in CHD suspected cases has also 
decreased. Although this could be true, our data show that a relatively high proportion of 
cases with identified MI/CHD undergo an autopsy both in SHEEP and in AMORIS. 
Information about the autopsy proportion among individuals classified as dead from CHD is 
not to be found in national statistics. The MONICA study has a relatively large 
documentation on autopsies in CHD cases between 1980 and 1995. Among the participating 
centers, the highest proportion of autopsy were found in Toulouse in France, New Zealand, 
the former Yugoslavia, US, Switzerland, Russia and Gothenburg in Sweden (110). The 
autopsy proportions in MI cases in SHEEP are quite similar as the ones found in Gothenburg 
city when the MONICA study took place.  
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Figure 7. Proportion of autopsies from 1987 to 2014, among all fatal events men and women, 
as well as in those aged 15-74 years in Sweden. Legends were translated from Swedish and 
the time scale was reformatted in order to reflect the calendar year. Source: Dodsorsaker 
2014 (Causes of Death 2014- In Swedish language) (83). 
6.3 REGISTER-BASED DATABASES (STUDIES I-IV)  
The studies included in this thesis are all to some extent based on data from national registers. 
The use of a unique 10-digit personal identification number in Sweden has made it possible 
to extract information about diagnoses at hospitalizations and causes of death during a 
follow-up period with virtually no loss to follow-up.  It also provided the possibility to extract 
data on socioeconomic indicators. 
6.4 CONFOUNDING (STUDIES II-IV) 
Considering the relatively limited knowledge about determinants of MI fatality, it is not 
evident what potential confounders to adjust for in the analyses of various potential risk 
factors considered in this thesis. Further, it may be difficult to distinguish between 
confounding factors and factors that have a role in the causal chain of mechanisms behind a 
fatal outcome. The possibility of uncontrolled confounding should be considered when 
interpreting the results from this thesis.  
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7 CONCLUSIONS 
This PhD thesis contributes to fill a void of knowledge regarding determinants of MI fatality. 
It also contributes to the limited scientific knowledge about validity of information collected 
from proxy respondents.    
Among the cardiometabolic factors considered in this thesis, diabetes and presence of a low-
grade inflammation were observed to associate with fatality of coronary events. No such 
associations were observed for hypertension, and hyperlipidemia. Further, our results seem to 
favor the “obesity paradox”, since individuals with overweight and obese individuals had 
lower fatality than those with a normal BMI.  
Our explorative approach to identify comorbidities in fatal MI cases revealed that the 
following were prevalent and also associated with increased MI fatality:  heart failure, 
diabetes, stroke, alcoholism, psychiatric disease, rheumatoid arthritis, asthma and epilepsy 
Our explorative approach to identify indicators of additional comorbidities in fatal MI, based 
on autopsy records, revealed presence of partial or total edentulism (data available only from 
forensic autopsy records), advanced atherosclerosis in the abdominal aorta, and hepatic 
steatosis.  
Low-grade inflammation was associated with an increased fatality of future coronary events 
of a cohort of healthy individuals at baseline.  
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8 FUTURE RESEARCH 
Time to treatment is the most important factor influencing MI fatality. To lower rates of MI 
fatality, efforts to shorten time to treatment in the acute phase are important. However, an 
improved understanding of other determinants of MI fatality is also needed. This thesis 
addresses the potential influences from cardiometabolic risk factors including a low-grade 
inflammation and from comorbidities. Several interesting associations were observed and 
possible avenues for future research include investigating whether treatments of low-grade 
inflammation will lower fatality of future MI events. The components of inflammation should 
also be better characterized. Future research may also address other potential risk factors of 
MI fatality. Future research may take advantage of novel imaging techniques in non-fatal MI 
cases which will allow comparisons to pathological findings in fatal cases.  
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9 SUMMARY IN SWEDISH 
 
Bakgrund 
Trots ett stort antal förbättringar i förebyggande och vård av kranskärlssjukdom (CHD) under 
senare år, var denna sjukdomsgrupp en av de främsta dödsorsakerna år 2010 runt om i 
världen. Majoriteten av dödsfallen i CHD inträffar utanför sjukhus och forskning kring 
riskfaktorer för död i samband med CHD-insjuknande, där dödsfallen utanför sjukhus 
beaktas, är begränsad. 
Mål 
Det övergripande syftet med projektet var att öka kunskapen om faktorer som bidrar till 
risken att avlida i samband med insjuknande i en förstagångs hjärtinfarkt i Stockholms 
allmänna befolkning. Specifika syften var att: 1) validera enkätuppgifter som samlats in från 
nära släktingar till hjärtinfarktpatienter, 2) bedöma hur kända kardiometabola riskfaktorer är 
förknippade med risken att avlida i samband med en hjärtinfarkt, 3) beskriva vilka andra 
sjukdomar som vanligen förekom hos individer som avled i samband med hjärtinfarkt samt 
bedöma om dessa sjukdomar är associerade till en fatal utgång av hjärtinfarkt, 4) bedöma om 
låggradig inflammation är associerad till död i samband med framtida insjuknande i 
koronarsjukdom. 
Metoder 
Utnyttjande studiematerial från Stockholm Heart Epidemiology Program (SHEEP), en fall-
kontrollstudie, värderades giltigheten av enkätuppgifter (82 variabler) som makar/sambor 
(proxy-respondenter) tillpatienter med icke-fatal hjärtinfarkt rapporterat. Med användning av 
villkorlig logistisk regression beräknade vi för var och en av exponeringarna, en ”proxy bias”, 
baserat på information som samlats in från 1) hjärtinfarkt-fall och kontroller [oddskvot A] 
och 2) ”proxies” och samma uppsättning kontroller [oddskvot B]. Oenighet mättes genom 
beräkning av förhållandet mellan oddskvot B och oddskvot A; 95% konfidensintervall (Cl) 
beräknades med s.k.  resampling bootstrap with replacement.  
Från SHEEP extraherades en kohort av alla förstagångs-fall av hjärtinfarkt. Data om 
exponeringar inhämtades från frågeformulär (ifyllda av en nära släkting om  fallet hade haft 
dödlig utgång), kroppsundersökningar (för icke-dödliga fall), nationella register och 
obduktionsrapporter. Associationer mellan utvalda kardiometabola riskfaktorer och 
hjärtinfarkt-fatalitetanalyserades genom beräkningar av riskkvoter (RR) med 95% 
konfidensintervall (Cl) under användning av binomial-regression med log link. Förekomst av 
andra sjukdomar, s.k. co-morbiditeter, bland de fatala hjärtinfarkt-fallen kartlades och antalet 
tidigare sjukhusinläggningar räknades. Samband mellan specifika sjukdomsdiagnoser samt 
antal tidigare sjukhusinläggningar och hjärtinfarkt-fatalitet analyseradesmed samma metod 
förmodellering som för kardiometabola riskfaktorer. En strukturerad genomgång av 
obduktionsuppgifter utfördes för att identifiera ytterligare indikatorer på sjukdomstillstånd 
hos fatala hjärtinfarkt-fall. 
Utnyttjande material från AMORIS-kohorten, analyserades könsspecifika associationer 
mellan låg-gradig inflammation (identifierad genom en poängskala byggd på mätningar i 
  33 
blod av fem olika biomarkörer: C-reaktivt protein, haptoglobin, antalet vita blodkroppar, 
urinsyra och albumin) och en dödlig utgång hos individer som under uppföljningstiden i 
AMORIS drabbades av en första koronar-händelse. Associationerna fastställdes genom 
beräkning av oddskvoter med 95% Cl under användning av logistisk regression. 
Resultat 
För de allra flesta av de exponeringar som beaktades i valideringsstudien fanns ingen 
statistiskt signifikant oenighet mellan rapporter från ”proxies” och hjärtinfarktpatienter. 
Emellertid överskattades fysisk inaktivitet på fritiden av ”proxies” jämfört med 
hjärtinfarktpatienter. 
Diabetes, men inte hypertoni och hyperlipidemi, var associerad med hjärtinfarkt-fatalitet. 
Övervikt, jämfört med normal BMI, var omvänt associerat med hjärtinfarkt-fatalitet; 
resultaten för fetma gick i samma riktning. Resultaten justerades för ålder, aktuell rökning, 
förtida hjärtdöd hos föräldrar, antal tidigare sjukhusinläggningar, utbildningsnivå, disponibel 
inkomst, och andra kardiometabola riskfaktorer. 
Antalet tidigare sjukhusinläggningar var associerat med hjärtinfarkt-fatalitet efter justering 
för kön, ålder och disponibel inkomst. Bland de co-morbiditetersom befanns relativt vanligt 
förekommande hos fatala fall och som efter justeringar (om möjliga) var associerade med 7-
dagars hjärtinfarkt-fatalitet var: hjärtsvikt, stroke, diabetes, alkoholism, psykiatriska 
sjukdomar, cancer, njursjukdomar, epilepsi, reumatoid artrit och astma. Indikatorer för 
sjukdomstillstånd utifrån obduktionsuppgifter var s.k. tyst hjärtinfarkt, grav åderförkalkning 
av bukaorta och lever-steatos. 
En låg-gradig inflammation var, efter justeringar (för ålder vid tidpunkten för den koronara 
händelsen, kalenderår för den koronara händelsen, diabetes, utbildningsnivå, serumnivå av 
totalkolesterol, serumnivå av triglycerider och angina) associerad med ökad dödlighet i 
samband med en framtida koronar händelse, hos både män och kvinnor. 
Slutsatser 
Hjärtinfarkt-patienter och deras makar/sambor rapporterade samstämmiga uppgifter om ett 
stort antal exponeringar som föregick insjuknandet hos patienten. Detta exponeringar 
innefattade traditionella kardiovaskulära riskfaktorer. Dock observerades oenighet 
beträffande rapporter om fysisk inaktivitet på fritiden. 
Bland de kardiometabola faktorer som studerades, befanns diabetes och förekomst av en 
låggradig inflammation, men inte hypertoni och hyperlipidemi, vara associerade med en ökad 
hjärtinfarkt-fatalitet. Övervikt var associerad med en minskad hjärtinfarkt-fatalitet. 
Upprepade tidigare sjukhusvistelser och/eller hjärtsvikt, diabetes, stroke, psykiatrisk 
sjukdom, alkoholism, cancer, njursjukdomar, epilepsi, reumatoid artrit och astma var 
associerade med ökad hjärtinfarkt-fatalitet.  
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10 SUMMARY IN SPANISH 
Antecedentes 
Aunque ha habido un gran número de mejoras en la prevención y atención de las 
enfermedades coronarias (EC), ésta fue una de las principales causas de muerte en el 2010 en 
todo el mundo. La mayoría de las muertes por EC se producen fuera del hospital y la 
investigación sobre los determinantes de la letalidad por EC donde se consideran tales 
muertes es escasa. 
Objetivos 
El objetivo general de este proyecto fue aumentar el conocimiento sobre los determinantes de 
la letalidad por EC en la población general de Estocolmo. Los objetivos específicos fueron: 1) 
validar los datos recopilados por parte de parientes cercanos de pacientes con infarto de 
miocardio (IM) en un cuestionario; 2) evaluar cómo los factores de riesgo cardiometabólico 
conocidos se asocian con la letalidad del IM; 3) describir qué comorbilidades son las más 
frecuentes entre los casos de IM fatal y evaluar si éstas están asociadas a la letalidad de IM, y 
4) evaluar si la inflamación de bajo grado se asocia con la fatalidad de futuros eventos 
coronarios. 
Métodos 
Utilizando material del Programa de Epidemiología del Corazón de Estocolmo (SHEEP, por 
sus siglas en inglés: “Stockholm Heart Epidemiology Program”, un estudio de casos y 
controles), se evaluó la validez de los datos de su cuestionario proporcionados por 
cónyuges/cónyuges de derecho consuetudinario (proxies) en casos de IM no fatales en 82 
variables. Utilizando regresión logística condicional, se calculó para cada una de las variables 
un "sesgo del proxy", basado en información recogida de 1) casos de IM y controles [odds 
ratio A] y 2) la de los proxies y el mismo conjunto de controles [odds ratio B]. El desacuerdo 
se midió calculando el cociente del odds ratio B dividido entre el odds ratio A; Los intervalos 
de confianza (IC) del 95% se calcularon utilizando el bootstrap de reemplazo con remuestreo. 
Del SHEEP, se formó una cohorte de casos incidentes con IM. Los datos se obtuvieron de los 
cuestionarios (rellenados por un familiar cercano si el caso era fatal), exámenes físicos (para 
casos no mortales), registros nacionales e informes de autopsias. Las asociaciones entre los 
factores de riesgo cardiometabólico seleccionados y la letalidad de IM se evaluaron mediante 
cálculos de las razones de riesgo (RR) con intervalos de confianza (IC) del 95% mediante 
regresión binomial con enlace logarítmico. Se determinó la presencia de comorbilidades entre 
los casos fatales de IM y se evaluó el número de hospitalizaciones previas. Las asociaciones 
entre comorbilidades específicas, así como el número de hospitalizaciones previas y la 
letalidad por IM fueron evaluadas utilizando el mismo modelo que para los factores de riesgo 
cardiometabólico. Se realizó una revisión estructurada de los datos de las autopsias para 
identificar indicadores adicionales de comorbilidades en casos de IM fatal. 
Utilizando material de la cohorte AMORIS, se valoraron las asociaciones entre la 
inflamación de bajo grado (usando una puntuación basada en cinco biomarcadores: los 
niveles séricos de la proteína C reactiva, los niveles séricos de haptoglobina, el recuento de 
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leucocitos, los niveles séricos de ácido úrico y los niveles séricos de albúmina) y la letalidad 
en sujetos que posteriormente experimentaron su primer evento coronario. Los odds ratios se 
calcularon con IC del 95% usando la regresión logística. 
Resultados 
Para la gran mayoría de las variables consideradas en el estudio de validación, no hubo 
desacuerdo estadísticamente significativo entre los informes de pacientes con IM y proxies. 
Sin embargo, la actividad física en el tiempo libre fue subestimada por los proxies en 
comparación con los pacientes con IM. 
La diabetes, mas no la hipertensión ni la hiperlipidemia, se asoció con la letalidad del MI. El 
sobrepeso, en comparación con el índice de masa corporal normal, se asoció inversamente 
con la letalidad de IMI. Los resultados para la obesidad apuntaron en la misma dirección de 
los del sobrepeso. Los resultados se ajustaron en función de la edad, el tabaquismo, la historia 
paterna de muerte cardiaca prematura, el número de hospitalizaciones previas, el nivel 
educativo, el ingreso disponible y otros factores de riesgo cardiometabólicos. 
Un  número mayor de hospitalizaciones precediendo el infarto se asoció con un aumento en 
la letalidad por IM después de ajustes por sexo, edad e ingreso disponible. Entre las 
comorbilidades identificadas como prevalentes en los casos de IM fatales, las siguientes 
fueron asociadas con un aumento de la letalidad a los 7 días: la insuficiencia cardíaca, el 
accidente cerebrovascular, la diabetes, el alcoholismo, la enfermedad psiquiátrica, el cáncer, 
las enfermedades renales, la epilepsia, la artritis reumatoide y el asma. Los indicadores de 
comorbilidades identificados a partir de datos de autopsia incluyeron el IM silencioso, la 
aterosclerosis aórtica abdominal severa, la esteatosis hepática y el bajo peso. 
Un puntaje de inflamación elevado después de los ajustar por edad en el momento del evento 
coronario, el año calendario del evento coronario, la diabetes, el nivel de educación, el 
colesterol total sérico, los triglicéridos séricos y la angina, se asoció con un aumento de la 
letalidad de futuros eventos coronarios, tanto en hombres como en mujeres. 
Conclusiones 
Tanto los pacientes con IM como sus cónyuges informaron de manera similar acerca de una 
amplia gama de variables, incluidas los tradicionales factores de riesgo cardiovascular, siendo 
la inactividad física durante el tiempo libre una excepción. 
Entre los factores cardiometabólicos en estudio, la diabetes y la presencia de la inflamación 
de bajo grado, pero no la hipertensión ni la hiperlipidemia, se asociaron con un aumento de la 
letalidad del IM. El exceso de peso se asoció con una disminución de la letalidad del IM. Las 
hospitalizaciones previas repetidas y/o la insuficiencia cardiaca, la diabetes, el accidente 
cerebrovascular, la enfermedad psiquiátrica, el alcoholismo, el cáncer, las enfermedades 
renales, la epilepsia, la artritis reumatoide y el asma se asociaron a un aumento en la letalidad 
del IM.  
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